The price of Insmed Incorporated (NASDAQ:INSM) shares last traded on Wall Street rose 5.71% to $19.98.
Based on available information, 13 analysts follow Insmed Incorporated (NASDAQ:INSM). The consensus rating among analysts is ‘Buy’. INSM stock price is now 6.64% away from the 50-day moving average and -7.26% away from the 200-day moving average. The market capitalization of the company currently stands at $2.80B.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Among analysts, 0 rate the stock a hold while 12 rate it a buy.
With the price target of $28, Mizuho recently initiated with Buy rating for Insmed Incorporated (NASDAQ: INSM). On December 07, 2022, Barclays recently initiated its ‘Overweight’ rating on the stock quoting a target price of $37, while ‘BofA Securities’ rates the stock as ‘Buy’.
In other news, Wise John Drayton, Chief Commercial Officer sold 7,154 shares of the company’s stock on Nov 22. The stock was sold for $134,781 at an average price of $18.84. Upon completion of the transaction, the Chief Commercial Officer now directly owns 71,613 shares in the company, valued at $1.43 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 22, Chief Operating Officer Adsett Roger sold 11,855 shares of the business’s stock. A total of $222,874 was realized by selling the stock at an average price of $18.80. This leaves the insider owning 134,127 shares of the company worth $2.68 million. Insiders disposed of 488,360 shares of company stock worth roughly $9.76 million over the past 1 year. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in INSM stock. A new stake in Insmed Incorporated shares was purchased by T. ROWE PRICE INVESTMENT MANAGEMENT, INC. during the first quarter worth $161,174,000. TANG CAPITAL MANAGEMENT LLC invested $9,990,000 in shares of INSM during the first quarter. In the first quarter, TWO SIGMA INVESTMENTS, LP acquired a new stake in Insmed Incorporated valued at approximately $5,926,000. PANAGORA ASSET MANAGEMENT INC acquired a new stake in INSM for approximately $5,705,000. J. GOLDMAN & CO LP purchased a new stake in INSM valued at around $3,669,000 in the second quarter. In total, there are 323 active investors with 96.90% ownership of the company’s stock.
A candlestick chart of Insmed Incorporated (NASDAQ: INSM) showed a price of $19.05 on Thursday morning. During the past 12 months, Insmed Incorporated has had a low of $16.41 and a high of $28.94. The fifty day moving average price for INSM is $18.74 and a two-hundred day moving average price translates $21.54 for the stock.
The latest earnings results from Insmed Incorporated (NASDAQ: INSM) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$1.09, missing analysts’ expectations of -$0.89 by -0.2. This compares to -$0.96 EPS in the same period last year. The company reported revenue of $67.73 million for the quarter, compared to $46.76 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 44.86 percent. For the current quarter, analysts expect INSM to generate $71.17M in revenue.
Insmed Incorporated(INSM) Company Profile
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
